What you are deciding between
Letybo (letibotulinumtoxinA-wlbg) is the sixth botulinum toxin type A product approved for aesthetic use in the United States. It joins Botox, Dysport, Xeomin, Jeuveau, and Daxxify in the neuromodulator category. All six work by the same mechanism — blocking acetylcholine release at the neuromuscular junction to temporarily relax targeted facial muscles. The differences between them come down to molecular formulation, onset speed, tissue spread, cost, and the depth of clinical evidence behind each product.
Letybo's FDA approval in February 2024 was supported by three Phase 3 trials (BLESS I, II, and III) enrolling over 1,200 subjects (see the FDA Drug Trials Snapshot for Letybo). Before entering the U.S., it had been marketed as Botulax in South Korea and distributed in approximately 69 countries under the name Letybo, where it has been the leading neurotoxin brand in South Korea for seven consecutive years according to manufacturer Hugel America.
According to NewBeauty's 2026 trend forecast (newbeauty.com), Yelp search interest in Letybo has climbed approximately 525% since its FDA approval, reflecting growing patient curiosity about the newest neuromodulator option.
This comparison focuses on Letybo versus the three most commonly used alternatives: Botox, Dysport, and Xeomin. Daxxify and Jeuveau are discussed where relevant but are not the primary comparison targets.
The basics at a glance
| Letybo | Botox | Dysport | Xeomin | |
|---|---|---|---|---|
| Generic name | LetibotulinumtoxinA-wlbg | OnabotulinumtoxinA | AbobotulinumtoxinA | IncobotulinumtoxinA |
| Manufacturer | Hugel (South Korea) | AbbVie/Allergan | Ipsen/Galderma | Merz |
| FDA approval (aesthetic) | February 2024 | 2002 | 2009 | 2010 |
| FDA-cleared indication | Moderate to severe glabellar lines | Glabellar lines, crow's feet, forehead lines, platysma bands | Moderate to severe glabellar lines | Glabellar lines, forehead lines, crow's feet (simultaneous) |
| Molecular structure | 900 kDa complex with accessory proteins | 900 kDa complex with accessory proteins | Complex with accessory proteins | "Naked" toxin — no accessory proteins |
| Labeled dose for glabella | 20 Units (5 sites × 4 U) | 20 Units (5 sites × 4 U) | 50 Units (5 sites × 10 U) | 20 Units (5 sites × 4 U) |
| Unit ratio to Botox | Approximately 1:1 | Reference | Approximately 2.5:1 to 3:1 | Approximately 1:1 |
| Typical onset | 3–5 days | 3–5 days | 2–3 days | 3–5 days |
| Typical duration | 3–4 months | 3–4 months | 3–4 months | 3–4 months |
| Storage | Refrigerated | Refrigerated | Refrigerated | Room temperature (before reconstitution) |
Mechanism: same toxin family, different formulations
All four products are botulinum toxin type A. The core neurotoxin — the 150 kDa clostridial protein that cleaves SNAP-25 and blocks acetylcholine release — is functionally the same across all of them. What differs is what surrounds that toxin in the vial.
Letybo ships as a complex including hemagglutinin and non-hemagglutinin accessory proteins, structurally similar to Botox. The FDA label (accessdata.fda.gov prescribing information) specifies a purified botulinum toxin type A produced by Clostridium botulinum fermentation. The manufacturing process involves Hugel's proprietary purification technology.
Botox has the same complex structure and has been the reference standard for over two decades. It has the broadest FDA-approved indications of any neuromodulator, including glabellar lines, crow's feet, forehead lines, and — as of October 2024 — platysma bands (AbbVie press release).
Dysport has a smaller protein complex, which some clinicians believe contributes to its wider tissue spread and faster onset. The labeled dose for glabellar lines is 50 units (approximately 2.5–3× the Botox unit count), reflecting a different potency assay.
Xeomin is the only "naked" toxin in this group — it contains purified botulinum toxin type A without accessory proteins. This is relevant for patients who may have developed neutralizing antibodies to the complexing proteins in other products, although antibody-mediated treatment failure is rare at cosmetic doses.
The FDA states explicitly that potency units are specific to each preparation and are not interchangeable. The clinical conversion ratios listed above (approximately 1:1 for Letybo/Botox/Xeomin, approximately 2.5–3:1 for Dysport) are consensus clinical conventions, not label conversions.
Onset: when results appear
| Product | Typical onset | Notes |
|---|---|---|
| Letybo | 3–5 days | Early clinical data suggests a timeline similar to Botox |
| Botox | 3–5 days | Peak effect at approximately 2 weeks |
| Dysport | 2–3 days | Generally the fastest onset of the group |
| Xeomin | 3–5 days | Slightly faster than Botox in some clinical reports |
Dysport has a consistent onset advantage of roughly 1–2 days over Botox and Xeomin. Letybo's onset appears comparable to Botox based on Phase 3 data, though head-to-head real-world comparisons are still limited because the product launched in the U.S. only in the second half of 2024.
A 2025 PMC study on the diffusion characteristics of letibotulinumtoxinA versus onabotulinumtoxinA (PMC 12256374) found comparable diffusion patterns between the two products, suggesting that Letybo's spread behavior is similar to Botox rather than to Dysport's wider diffusion profile.
Duration: how long results last
All four products — Letybo, Botox, Dysport, and Xeomin — have a typical duration of 3 to 4 months for cosmetic indications. This is based on:
- Letybo's BLESS trials, where the primary efficacy endpoint was assessed at Week 4 and the FDA label notes duration consistent with the neuromodulator class.
- Botox's extensive post-marketing experience over 20+ years.
- Dysport and Xeomin's respective pivotal trials and real-world use.
Daxxify is the only neuromodulator with a label-supported median duration of approximately 6 months, owing to its peptide excipient (RTP-004). If duration beyond 4 months is a priority, Daxxify — not Letybo — is the relevant alternative.
Individual results vary. Factors that affect duration include dose, injection technique, muscle mass, metabolic rate, and treatment area.
Tissue spread and precision
This is where the neuromodulators behave differently in practice.
Letybo appears to have a diffusion pattern similar to Botox — relatively localized spread with a controlled distribution. The PMC diffusion study cited above supports this characterization. Some early-adopter providers have reported that Letybo produces a "smooth, even" result, though this is anecdotal and not captured in the pivotal trial data.
Dysport is known for wider tissue spread, which can be advantageous for treating broad areas like the forehead but may be less desirable around the eyes or mouth where precision matters.
Xeomin and Botox have similar, relatively localized spread patterns.
For patients concerned about a "frozen" look or unwanted effects on adjacent muscles, Letybo's diffusion profile (similar to Botox) means it can be used in the same targeted approach. For those who want the broader coverage that Dysport's spread provides, switching to Letybo may produce a more localized result.
Cost comparison
Pricing data from 2025 med-spa surveys and provider websites (see Express Med Spa Letybo pricing) shows:
| Product | Average price per unit | Typical cost for glabellar lines (20 Botox-equivalent units) |
|---|---|---|
| Letybo | $9–$13 | $180–$260 |
| Botox | $12–$16 | $240–$320 |
| Dysport | $4–$6 (requires ~2.5× units) | $200–$300 |
| Xeomin | $10–$14 | $200–$280 |
Letybo's lower per-unit cost — roughly 10–20% less than Botox for an equivalent treatment — is one of its primary commercial advantages. As a newer entrant, Hugel is pricing Letybo competitively to gain market share.
However, cost should not be the only decision factor. A product that is 15% cheaper but administered by an inexperienced injector can produce worse outcomes. The total treatment cost, not the per-unit price, is what matters.
Immunogenicity and resistance
All botulinum toxin type A products carry a risk of immunogenicity — the body can develop neutralizing antibodies that reduce or eliminate treatment effectiveness over time. At cosmetic doses, this risk is very low across all products.
Xeomin has the theoretical advantage of being free of accessory proteins, which means there are fewer foreign proteins to trigger an immune response. For patients who have stopped responding to Botox or other complexed toxins, Xeomin is the standard recommendation.
Letybo, like Botox, contains complexing proteins. There is no evidence from the BLESS trials or post-marketing surveillance suggesting that Letybo has a higher immunogenicity risk than Botox, but the product has only been in the U.S. market since 2024 and long-term real-world data is still accumulating.
The FDA's boxed warning on all botulinum toxin products, including Letybo, notes that effects can spread from the injection site and cause serious adverse effects including difficulty swallowing and breathing (Letybo prescribing information). This risk exists at therapeutic (high) doses and is extremely rare at cosmetic doses.
The BLESS trials: what the evidence actually shows
Letybo's FDA approval was supported by three identically designed Phase 3 trials:
- BLESS I (NCT02677298)
- BLESS II (NCT02677805)
- BLESS III (NCT03985982)
Across all three trials, 1,276 subjects were randomized 3:1 to receive a single 20-unit treatment of Letybo (n=957) or placebo (n=319). The primary endpoint was the proportion of subjects achieving a score of 0 or 1 (none or mild) with at least a 2-grade improvement from baseline at maximum frown at Week 4.
Results from the FDA Drug Trials Snapshot:
| Trial | Letybo responder rate | Placebo responder rate |
|---|---|---|
| BLESS I | 48.1% (under 65) / 36.4% (65–75) | 0% |
| BLESS II | 51.8% (under 65) / 26.3% (65–75) | 2.2% |
| BLESS III | 66.5% (under 65) / 51.5% (65–75) | 0% |
The responder rate was meaningfully lower in the 65–75 age group across all three trials — a pattern also seen with other neuromodulators, likely reflecting deeper, more static wrinkles in older patients.
Who should consider Letybo
Letybo may be a reasonable option for:
- Patients new to neuromodulators who want to try a product with a similar onset and duration to Botox at a lower cost.
- Patients currently on Botox who are price-sensitive and want a 1:1 unit conversion product.
- Providers experienced with Botox who can use the same injection technique and dosing approach.
Letybo is not the best choice for:
- Patients who want the longest possible duration — Daxxify is the product with label-supported 6-month median duration.
- Patients who want the fastest onset — Dysport's 2–3 day onset is faster.
- Patients with suspected antibody resistance — Xeomin's "naked" formulation is the standard recommendation.
- Patients who want FDA-cleared treatment for multiple areas — Letybo is only approved for glabellar lines, while Botox has additional approvals for crow's feet, forehead lines, and platysma bands.
When none of these is right
If you have active infections at the injection site, are pregnant or breastfeeding, have a known hypersensitivity to botulinum toxin, or have a neuromuscular disorder (such as myasthenia gravis or Lambert-Eaton syndrome), neuromodulator treatment is contraindicated regardless of which product is being considered.
If your primary concern is volume loss rather than dynamic wrinkles, a neuromodulator is the wrong tool — dermal fillers or biostimulators may be more appropriate.
Questions to ask before choosing
- What areas are being treated? If it is only the glabellar lines, all four products are options. If you also want crow's feet or forehead lines, Botox has the broadest FDA-cleared indications.
- What is the total cost? Compare total treatment cost, not per-unit price. Ask your provider for a written quote.
- Does your provider have experience with this specific product? Letybo launched in the U.S. in late 2024, so many providers have less experience with it than with Botox or Dysport.
- Have you had neutralizing antibody issues before? If so, Xeomin is the standard recommendation.
- Is fast onset a priority? If you are treating before an event, Dysport's faster onset may be advantageous.
Sources
- U.S. FDA. Drug Trials Snapshot: Letybo. fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-letybo
- U.S. FDA. Letybo (letibotulinumtoxinA-wlbg) Prescribing Information. accessdata.fda.gov/drugsatfda_docs/label/2024/761225s000lbl.pdf
- U.S. FDA. BLA 761225 Clinical Review and Evaluation Memorandum. accessdata.fda.gov/drugsatfda_docs/nda/2024/761225Orig1s000MultidisciplineR.pdf
- Hugel America. Press Release: FDA Approval of Letybo. March 4, 2024. hugel-aesthetics.com/news-press-releases
- American Board of Cosmetic Surgery. Letybo is the Latest Botox Alternative to Get FDA Approval. americanboardcosmeticsurgery.org/blog/letybo-new-botox-alternative-fda-approval
- Diffusion Characteristics of LetibotulinumtoxinA versus OnabotulinumtoxinA. PMC, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12256374
- Aesthetic Training. FDA-Approved Botulinum Toxins for Aesthetic Use Comparison. aesthetic-training.com/fda-approved-botulinum-toxins-for-aesthetic-use-comparison
